Stock Detail
Videos
PolyPid Ltd. (PYPD) Company Webcast
This company webcast features PolyPid Ltd. (Nasdaq: PYPD). PolyPid is a late-stage biopharma company aiming to improve surgical outcomes. This company webcast was recorded during the Lytham Partners 2025 Investor Healthcare Summit.
PolyPid (PYPD) Company Webcast
During this presentation we welcome, PolyPid. PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. PolyPid’s lead product candidate D-PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical...
News
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
PETACH TIKVA, Israel, Jan. 30, 2025 -- PolyPid Ltd. (Nasdaq: PYPD), ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will present at the Oppenheimer 35th Annual Healthcare...
PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025
PETACH TIKVA, Israel, Jan. 29, 2025 -- PolyPid Ltd. (Nasdaq: PYPD) ("PolyPid" or the "Company"), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2024 financial results and...
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX to 800 Patients with a Concurrent Private Placement of up to $41 Million
630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025; Upon Potential Positive Phase 3 Data the Company Expects to Submit a New Drug Application ("NDA") for D-PLEX100 under Fast Track and Breakthrough...